Rational Vaccine Design against Malaria
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against Infectious Diseases".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 2698
Special Issue Editors
Interests: malaria; vaccine; attenuated parasites; antigens; infectious diseases; structural vaccinology
Interests: therapeutic proteins; vaccine targets; infectious diseases
Interests: RNA-based therapeutics; infectious diseases; structural biology
Special Issue Information
Dear Colleagues,
Malaria remains one of the most devastating and life-threatening diseases worldwide that causes more than half a million deaths annually. The currently available malaria vaccine, RTS,S/AS01, can prevent malaria in young African children noting a 30% reduction in deadly severe anemia. However, higher vaccine efficacy is much needed. Therefore, it is necessary to identify potential vaccine candidates to elicit more robust protective responses against malaria. In light of malaria parasites' available genomic, proteomic, and metabolomic information, it is the most promising time to switch from traditional empirical approaches to advanced, rational designs, and to identify potent malaria vaccine candidates.
We are pleased to invite you to submit your manuscript related to novel strategies for malaria vaccine design. We welcome original research articles describing novel malaria vaccine candidates based on (but not limited to) parasite-focused and reverse vaccinology, structural vaccinology, and/or immunoinformatics.
Dr. Hirdesh Kumar
Dr. Peeyush Ranjan
Dr. Vinay Kumar
Dr. Sarita Puri Mishra
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- malaria
- vaccine
- Plasmodium
- attenuated parasites
- antigens
- adjuvants
- vaccine design
- subunit vaccine
- vaccine efficacy
- vaccine design
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
